Back to drug

The Drug-Induced Respiratory Disease Website and App

Frequency - Incidence

Incidence of respiratory adverse event(s) due to the specific drug as assessed by number of reported/published cases in the literature. Red digits in stars indicate: 0 = Very rare, questionable signal · 1 = < 10 cases · 2 = 10-50 cases · 3 = 50–100 cases · 4 = 100-200 cases · 5 = >200 cases

Evidence level/grade

Evidence level for respiratory adverse event(s) due to the specific drug as estimated using Hill’s (1965), Naranjo’s (1981), and Bégaud’s (1985) criteria applied to published cases. Blue digits in stars indicate: 0 = Questionable · 1 = Low · 2 = Moderate · 3 = Robust · 4 = Definite · 5 = Unquestionable, pathognomonic

I.b

Pneumonitis (interstitial lung disease/ILD)

Publications

Omotani S, Ishizaka T, Inoue M, Nishida K, Yasui Y, Hatsuda Y, Mukai J, Myotoku M

Drug-induced lung disease adverse effect with Ledipasvir Acetonate/Sofosbuvir.

Journal of pharmaceutical health care and sciences. 2020;6:6

Wong YJ, Chew SY, Hsiang JC, Thurairajah PH, Kumar R, Teo EK, Gokhale RS, Noor IBM, Tan J

VIEKIRA PAK associated drug-induced interstitial lung disease: Case series with systematic review of literature.

Clinical and molecular hepatology. 2019;25(2):218-222

Tarao K, Yamada K

A Hepatitis C Virus-Associated Cirrhotic Patient Developing Interstitial Pneumonia during the Course of Antiviral Therapy with Ombitasvir/Paritaprevir/Ritonavir.

Case reports in gastroenterology. 2017;11(2):369-376

Kawaoka T, Imamura M, Morio K, Nakamura Y, Tsuge M, Nelson Hayes C, Kawakami Y, Aikata H, Ochi H, Ishiyama K, Ohdan H, Chayama K

Three patients treated with sofosbuvir plus ledipasvir for recurrent hepatitis C after liver transplantation.

Clinical journal of gastroenterology. 2017;10(2):179-184

Helmers RA, Byrne TJ, Wesselius LJ, Leslie KO

Serious Pulmonary Toxicity Secondary to Novel Hepatitis C Antiviral Therapy in a Liver Transplant Recipient.

Mayo Clinic proceedings. 2015;90(9):1294-7